269 related articles for article (PubMed ID: 16627223)
1. Efficacy and safety of ertapenem versus piperacillin-tazobactam for the treatment of intra-abdominal infections requiring surgical intervention.
Dela Pena AS; Asperger W; Köckerling F; Raz R; Kafka R; Warren B; Shivaprakash M; Vrijens F; Giezek H; DiNubile MJ; Chan CY;
J Gastrointest Surg; 2006 Apr; 10(4):567-74. PubMed ID: 16627223
[TBL] [Abstract][Full Text] [Related]
2. Randomized, multicenter, double-blind study of efficacy, safety, and tolerability of intravenous ertapenem versus piperacillin/tazobactam in treatment of complicated intra-abdominal infections in hospitalized adults.
Namias N; Solomkin JS; Jensen EH; Tomassini JE; Abramson MA
Surg Infect (Larchmt); 2007 Feb; 8(1):15-28. PubMed ID: 17381394
[TBL] [Abstract][Full Text] [Related]
3. Ertapenem versus piperacillin-tazobactam for treatment of mixed anaerobic complicated intra-abdominal, complicated skin and skin structure, and acute pelvic infections.
Tellado J; Woods GL; Gesser R; McCarroll K; Teppler H
Surg Infect (Larchmt); 2002; 3(4):303-14. PubMed ID: 12697078
[TBL] [Abstract][Full Text] [Related]
4. Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial.
Solomkin JS; Yellin AE; Rotstein OD; Christou NV; Dellinger EP; Tellado JM; Malafaia O; Fernandez A; Choe KA; Carides A; Satishchandran V; Teppler H;
Ann Surg; 2003 Feb; 237(2):235-45. PubMed ID: 12560782
[TBL] [Abstract][Full Text] [Related]
5. Ertapenem versus piperacillin/tazobactam for diabetic foot infections in China: a Phase 3, multicentre, randomized, double-blind, active-controlled, non-inferiority trial.
Xu ZR; Ran XW; Xian Y; Yan XD; Yuan GY; Mu SM; Shen JF; Zhang BS; Gan WJ; Wang J
J Antimicrob Chemother; 2016 Jun; 71(6):1688-96. PubMed ID: 26888908
[TBL] [Abstract][Full Text] [Related]
6. Ertapenem versus piperacillin/tazobactam for the treatment of complicated infections: a meta-analysis of randomized controlled trials.
An MM; Zou Z; Shen H; Zhang JD; Chen ML; Liu P; Wang R; Jiang YY
BMC Infect Dis; 2009 Dec; 9():193. PubMed ID: 19951447
[TBL] [Abstract][Full Text] [Related]
7. Comparative activity of ertapenem and piperacillin tazobactam in a murine systemic infection model with Bacteroides fragilis and Escherichia coli.
Santos KVD; Nicoli JR; Martins WA; Coutinho SC; Apolônio ACM; Diniz CG; Carvalho MAR; Farias LM
J Med Microbiol; 2007 Nov; 56(Pt 11):1576-1579. PubMed ID: 17965366
[No Abstract] [Full Text] [Related]
8. Effect of body mass index on treatment of complicated intra-abdominal infections in hospitalized adults: comparison of ertapenem with piperacillin-tazobactam.
Zakrison TL; Hille DA; Namias N
Surg Infect (Larchmt); 2012 Feb; 13(1):38-42. PubMed ID: 22217196
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness evaluation of ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections accounting for antibiotic resistance.
Jansen JP; Kumar R; Carmeli Y
Value Health; 2009; 12(2):234-44. PubMed ID: 20667059
[TBL] [Abstract][Full Text] [Related]
10. Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin-tazobactam therapy for intraabdominal infections.
DiNubile MJ; Chow JW; Satishchandran V; Polis A; Motyl MR; Abramson MA; Teppler H
Antimicrob Agents Chemother; 2005 Aug; 49(8):3217-21. PubMed ID: 16048928
[TBL] [Abstract][Full Text] [Related]
11. Treatment of polymicrobial infections: post hoc analysis of three trials comparing ertapenem and piperacillin-tazobactam.
Solomkin J; Teppler H; Graham DR; Gesser RM; Meibohm AR; Roy S; Woods GL
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii51-7. PubMed ID: 15150183
[TBL] [Abstract][Full Text] [Related]
12. [New Beta-lactam agent in the treatment of intra-abdominal sepsis: double blind and randomized stage III study of ertapenem versus piperacillin/tazobactam].
Barboza E; Solomkin J; Goldstein EJ; del Castillo M; Alvarado R; Barboza A; Teppler H
Rev Gastroenterol Peru; 2003; 23(3):192-8. PubMed ID: 14532920
[TBL] [Abstract][Full Text] [Related]
13. Safety and tolerability of ertapenem.
Teppler H; Gesser RM; Friedland IR; Woods GL; Meibohm A; Herman G; Mistry G; Isaacs R
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii75-81. PubMed ID: 15150186
[TBL] [Abstract][Full Text] [Related]
14. Comparative costs of ertapenem and piperacillin-tazobactam in the treatment of diabetic foot infections.
Tice AD; Turpin RS; Hoey CT; Lipsky BA; Wu J; Abramson MA
Am J Health Syst Pharm; 2007 May; 64(10):1080-6. PubMed ID: 17494908
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of outpatient treatment with ertapenem in a double blind controlled clinical trial of complicated skin/skin structure infections.
Gesser RM; McCarroll KA; Woods GL
J Infect; 2004 Jan; 48(1):32-8. PubMed ID: 14667790
[TBL] [Abstract][Full Text] [Related]
16. Results of the North American trial of piperacillin/tazobactam compared with clindamycin and gentamicin in the treatment of severe intra-abdominal infections. Investigators of the Piperacillin/Tazobactam Intra-abdominal Infection Study Group.
Eur J Surg Suppl; 1994; (573):61-6. PubMed ID: 7524798
[TBL] [Abstract][Full Text] [Related]
17. Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study.
Graham DR; Lucasti C; Malafaia O; Nichols RL; Holtom P; Perez NQ; McAdams A; Woods GL; Ceesay TP; Gesser R
Clin Infect Dis; 2002 Jun; 34(11):1460-8. PubMed ID: 12015692
[TBL] [Abstract][Full Text] [Related]
18. Impact of a Dynamic Microbiological Environment on the Clinical Efficacy of Ertapenem and Piperacillin/Tazobactam in the Treatment of Complicated Community-Acquired Intra-Abdominal Infection in Spain: A Cost-Consequence Analysis.
Grau S; Lozano V; Valladares A; Cavanillas R; Xie Y; Nocea G
Appl Health Econ Health Policy; 2015 Aug; 13(4):369-79. PubMed ID: 25761545
[TBL] [Abstract][Full Text] [Related]
19. Accounting for the development of antibacterial resistance in the cost effectiveness of ertapenem versus piperacillin/tazobactam in the treatment of diabetic foot infections in the UK.
Jansen JP; Kumar R; Carmeli Y
Pharmacoeconomics; 2009; 27(12):1045-56. PubMed ID: 19908928
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of ertapenem in the treatment of serious infections caused by Enterobacteriaceae: analysis of pooled clinical trial data.
Gesser RM; McCarroll K; Teppler H; Woods GL
J Antimicrob Chemother; 2003 May; 51(5):1253-60. PubMed ID: 12697633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
